Showing session: reset
Immuno-oncology Clinical Trials I
- Sort by:
- Browse by:
- Free
- slides video
- audio + slides
- All slides included
Initial report of overall survival rates from a randomized phase II trial evaluating the combination of nivolumab (NIVO) and ipilimumab (IPI) in patients with advanced melanoma (MEL)
Michael Postow
Memorial Sloan Kettering Cancer Center, New York, NY, United States
- Free
- audio + slides
- Some slides withheld
Discussant
Padmanee Sharma
UT MD Anderson Cancer Center, Houston, TX, United States
- Free
- slides video
- audio + slides
- All slides included
KEYNOTE-006: PD-L1 expression and efficacy in patients (Pts) treated with pembrolizumab (pembro) vs ipilimumab (IPI) for advanced melanoma
Matteo Carlino
Crown Princess Mary Cancer Centre, Westmead and Blacktown Hospitals, Wentworthville, Australia
- Free
- slides video
- audio + slides
- All slides included
Discussant
Charles G. Drake
Johns Hopkins Kimmel Comp. Cancer Center, Baltimore, MD, United States
- Free
- slides video
- audio + slides
- All slides included
A phase I study of an HLA-DPB1*0401-restricted T-cell receptor targeting MAGE-A3 for patients with metastatic cancer
Yong-Chen Lu
National Institutes of Health, Bethesda, MD, United States
- Free
- slides video
- audio + slides
- All slides included
Durable, long-term survival in previously treated patients with advanced melanoma (MEL) who received nivolumab (NIVO) monotherapy in a phase I trial
F. Stephen Hodi
Dana-Farber Cancer Institute, Boston, MA, United States
- Free
- slides video
- audio + slides
- All slides included
Discussant
Jedd D Wolchok
Memorial Sloan Kettering Cancer Center, New York, NY, United States